Quantity of eligible sufferers: CDEC talked about the uncertainty in the quantity of clients with reasonably critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle or moderate disease may have a intense bleed